Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Hepatology International
Erschienen in: Hepatology International 5/2019

27.07.2019 | Review Article

Clinical immunology and immunotherapy for hepatocellular carcinoma: current progress and challenges

verfasst von: Lifeng Wang, Fu-Sheng Wang

Erschienen in: Hepatology International | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

At the time of hepatocellular carcinoma (HCC) diagnosis, patients are most often at an advanced stage; however, the current treatment regimens remain unsatisfactory. Thus, novel and more powerful therapeutic approaches for advanced HCC are urgently required. Exacerbation of immunotolerant signals and/or escaping immunosurveillance leads to the development of HCC, which appears to be a rational reason to use immunotherapy to restore anticancer immunity. Several novel immunotherapeutic methods, including the use of immune checkpoint inhibitors, new types of immune cell adoption [e.g., chimeric antigen receptor T cell (CAR-T), TCR gene-modified T cells and stem cells], and microRNAs have been used in clinical trials for the treatment of HCC. However, some crucial issues remain to be addressed for such novel immunotherapy techniques. Finally, immunotherapy is now standing on the threshold of great advances in the fight against HCC.
Literatur
1.
Wallace MC, Preen D, Jeffrey GP, Adams LA. The evolving epidemiology of hepatocellular carcinoma: a global perspective. Expert Rev Gastroenterol Hepatol 2015;9(6):765–779CrossRefPubMed
2.
3.
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63(1):11–30CrossRef
4.
Song P, Cai Y, Tang H, Li C, Huang J. The clinical management of hepatocellular carcinoma worldwide: a concise review and comparison of current guidelines from 2001 to 2017. Biosci Trends 2017;11(4):389–398CrossRefPubMed
5.
Llovet JM, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4):378–390CrossRef
6.
Kudo M, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018;391(10126):1163–1173CrossRefPubMed
7.
Bruix J, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389(10064):56–66CrossRef
8.
Allaire M, Nault JC. Advances in management of hepatocellular carcinoma. Curr Opin Oncol 2017;29(4):288–295CrossRefPubMed
9.
Kubes P, Jenne C. Immune responses in the liver. Annu Rev Immunol 2018;26(36):247–277CrossRef
10.
Ringelhan M, Pfister D, O’Connor T, Pikarsky E, Heikenwalder M. The immunology of hepatocellular carcinoma. Nat Immunol 2018;19(3):222–232CrossRefPubMed
11.
Nishida N, Kudo M. Immunological microenvironment of hepatocellular carcinoma and its clinical implication. Oncology 2017;92(Suppl 1):40–49CrossRefPubMed
12.
13.
Gelu-Simeon M, Samuel D. Role of cytokine levels in assessment of prognosis and post-treatment outcome in hepatocellular carcinoma. Hepatol Int 2013;7(3):788–791CrossRefPubMed
14.
Malfettone A, et al. Transforming growth factor-beta-induced plasticity causes a migratory stemness phenotype in hepatocellular carcinoma. Cancer Lett 2017;392:39–50CrossRefPubMed
15.
16.
Saalim M, et al. IL-22: a promising candidate to inhibit viral-induced liver disease progression and hepatocellular carcinoma. Tumour Biol 2016;37(1):105–114CrossRefPubMed
17.
18.
Liu H, et al. Roles of chemokine receptor 4 (CXCR18) and chemokine ligand 12 (CXCL12) in metastasis of hepatocellular carcinoma cells. Cell Mol Immunol 2008;5(5):373–378CrossRefPubMedPubMedCentral
19.
Qin LF, et al. CXCL12 and CXCR19 polymorphisms and expressions in peripheral blood from patients of hepatocellular carcinoma. Future Oncol 2018;14(13):1261–1271CrossRefPubMed
20.
Liang CM, et al. Chemokines and their receptors play important roles in the development of hepatocellular carcinoma. World J Hepatol 2015;7(10):1390–1402CrossRefPubMedPubMedCentral
21.
Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992;11(11):3887–3895CrossRefPubMedPubMedCentral
22.
Gao Q, et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res 2009;15(3):971–979CrossRefPubMed
23.
Shi F, et al. PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer 2011;128(4):887–896CrossRefPubMed
24.
Long J, et al. Expression of programmed death ligand-1 and programmed death 1 in hepatocellular carcinoma and its clinical significance. J Cancer Res Ther 2018;14(Supplement):S1188–S1192PubMed
25.
Zeng Z, et al. Upregulation of circulating PD-L1/PD-1 is associated with poor post-cryoablation prognosis in patients with HBV-related hepatocellular carcinoma. PLoS One 2011;6(9):e23621CrossRefPubMedPubMedCentral
26.
Jung HI, et al. Overexpression of PD-L1 and PD-L2 is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer Res Treat 2017;49(1):246–254CrossRefPubMed
27.
Gu X, et al. +49G > A polymorphism in the cytotoxic T-lymphocyte antigen-4 gene increases susceptibility to hepatitis B-related hepatocellular carcinoma in a male Chinese population. Hum Immunol 2010;71(1):83–87CrossRefPubMed
28.
Chen X, Du Y, Hu Q, Huang Z. Tumor-derived CD4+ CD25+ regulatory T cells inhibit dendritic cells function by CTLA-4. Pathol Res Pract 2017;213(3):245–249CrossRefPubMed
29.
Inada Y, et al. Characteristics of immune response to tumor-associated antigens and immune cell profile in hepatocellular carcinoma patients. Hepatology 2019;69(2):653–665CrossRefPubMed
30.
Monney L, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 2002;415(6871):536–541CrossRefPubMed
31.
Li H, et al. Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. Hepatology 2012;56(4):1342–1351CrossRefPubMed
32.
Yan W, et al. Tim-3 fosters HCC development by enhancing TGF-beta-mediated alternative activation of macrophages. Gut 2015;64(10):1593–1604CrossRefPubMed
33.
Li F, et al. Highly elevated soluble Tim-3 levels correlate with increased hepatocellular carcinoma risk and poor survival of hepatocellular carcinoma patients in chronic hepatitis B virus infection. Cancer Manag Res 2018;10:941–951CrossRefPubMedPubMedCentral
34.
Khan FS, Ali I, Afridi UK, Ishtiaq M, Mehmood R. Epigenetic mechanisms regulating the development of hepatocellular carcinoma and their promise for therapeutics. Hepatol Int 2017;11(1):45–53CrossRefPubMed
35.
Xie H, et al. microRNA-889 is downregulated by histone deacetylase inhibitors and confers resistance to natural killer cytotoxicity in hepatocellular carcinoma cells. Cytotechnology 2018;70(2):513–521CrossRefPubMed
36.
Xu D, Han Q, Hou Z, Zhang C, Zhang J. miR-146a negatively regulates NK cell functions via STAT1 signaling. Cell Mol Immunol 2017;14(8):712–720CrossRefPubMed
37.
Bian X, et al. Down-expression of miR-152 lead to impaired anti-tumor effect of NK via upregulation of HLA-G. Tumour Biol 2016;37(3):3749–3756CrossRefPubMed
38.
Abdelrahman MM, et al. Enhancing NK cell cytotoxicity by miR-182 in hepatocellular carcinoma. Hum Immunol 2016;77(8):667–673CrossRefPubMed
39.
Zhou SL, et al. miR-28-5p-IL-34-macrophage feedback loop modulates hepatocellular carcinoma metastasis. Hepatology 2016;63(5):1560–1575.CrossRefPubMed
40.
41.
42.
Wang H, et al. Reciprocal control of miR-197 and IL-6/STAT3 pathway reveals miR-197 as potential therapeutic target for hepatocellular carcinoma. Oncoimmunology 2015;4(10):e1031440CrossRefPubMedPubMedCentral
43.
Liu X, Zhang A, Xiang J, Lv Y, Zhang X. miR-451 acts as a suppressor of angiogenesis in hepatocellular carcinoma by targeting the IL-6R-STAT3 pathway. Oncol Rep 2016;36(3):1385–1392CrossRefPubMed
44.
Sandbothe M, et al. The microRNA-449 family inhibits TGF-beta-mediated liver cancer cell migration by targeting SOX4. J Hepatol 2017;66(5):1012–1021CrossRefPubMed
45.
Zhang T, et al. Downregulation of miR-542-3p promotes cancer metastasis through activating TGF-beta/Smad signaling in hepatocellular carcinoma. Onco Targets Ther 2018;11:1929–1939CrossRefPubMedPubMedCentral
46.
47.
Prieto J, Melero I, Sangro B. Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2015;12(12):681–700CrossRefPubMed
48.
Sangro B, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 2013;59(1):81–88CrossRefPubMed
49.
Duffy AG, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol 2017;66(3):545–551CrossRefPubMed
50.
El-Khoueiry AB, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389(10088):2492–2502CrossRef
51.
Truong P, Rahal A, Kallail KJ. Metastatic hepatocellular carcinoma responsive to pembrolizumab. Cureus 2016;8(6):e631PubMedPubMedCentral
52.
Wehrenberg-Klee E, Goyal L, Dugan M, Zhu AX, Ganguli S. Y-90 Radioembolization combined with a PD-1 inhibitor for advanced hepatocellular carcinoma. Cardiovasc Interv Radiol 2018;41(11):1799–1802CrossRef
53.
54.
Liu CQ, et al. Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma. Br J Cancer 2018;119(1):80–88CrossRefPubMedPubMedCentral
55.
56.
Takayama T, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000;356(9232):802–807CrossRefPubMed
57.
Shi M, et al. Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma. World J Gastroenterol 2004;10(8):1146–1151CrossRefPubMedPubMedCentral
58.
European Association for the Study of the Liver. Electronic address IEEE, European Association for the Study of the L. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol 2018;69(1):182–236CrossRef
59.
Flecken T, et al. Immunodominance and functional alterations of tumor-associated antigen-specific CD8 + T-cell responses in hepatocellular carcinoma. Hepatology 2014;59(4):1415–1126CrossRefPubMedPubMedCentral
60.
Zhou G, et al. Antibodies against immune checkpoint molecules restore functions of tumor-infiltrating T cells in hepatocellular carcinomas. Gastroenterology 2017;153(4):1107–1119CrossRefPubMed
61.
Desrichard A, Snyder A, Chan TA. Cancer neoantigens and applications for immunotherapy. Clin Cancer Res 2016;22(4):807–812CrossRefPubMed
62.
Gao H, et al. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma. Clin Cancer Res 2014;20(24):6418–6428CrossRefPubMed
63.
Chen C, et al. Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma. Cancer Immunol Immunother 2017;66(4):475–489CrossRefPubMed
64.
65.
Chen Y, et al. Chimeric antigen receptor-engineered T-cell therapy for liver cancer. Hepatobiliary Pancreat Dis Int 2018;17(4):301–309CrossRefPubMed
66.
Qasim W, et al. Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient. J Hepatol 2015;62(2):486–491CrossRefPubMed
67.
Spear TT, et al. TCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumors. Cancer Immunol Immunother 2016;65(3):293–304CrossRefPubMedPubMedCentral
68.
Zhu W, et al. Identification of alpha-fetoprotein-specific T-cell receptors for hepatocellular carcinoma immunotherapy. Hepatology 2018;68(2):574–589CrossRefPubMed
69.
70.
Wang X, et al. Phase I trial of active specific immunotherapy with autologous dendritic cells pulsed with autologous irradiated tumor stem cells in hepatitis B-positive patients with hepatocellular carcinoma. J Surg Oncol 2015;111(7):862–867CrossRefPubMedPubMedCentral
71.
Wang H, Wang J, Shi X, Ding Y. Genetically engineered bone marrow-derived mesenchymal stem cells co-expressing IFN-gamma and IL-10 inhibit hepatocellular carcinoma by modulating MAPK pathway. J BUON 2017;22(6):1517–1524PubMed
72.
73.
Fu J, et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007;132(7):2328–2339CrossRefPubMed
74.
Greten TF, et al. Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC. J Immunother 2010;33(2):211–218CrossRefPubMed
75.
Beg MS, et al. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Investig New Drugs 2017;35(2):180–188CrossRef
76.
Zhuang L, et al. Activity of IL-12/15/18 primed natural killer cells against hepatocellular carcinoma. Hepatol Int 2019;13(1):75–83CrossRefPubMed
77.
Sun F, Wang JZ, Luo JJ, Wang YQ, Pan Q. Exosomes in the oncobiology, diagnosis, and therapy of hepatic carcinoma: a new player of an old game. Biomed Res Int 2018;2018:2747461PubMedPubMedCentral
Metadaten
Titel
Clinical immunology and immunotherapy for hepatocellular carcinoma: current progress and challenges
verfasst von
Lifeng Wang
Fu-Sheng Wang
Publikationsdatum
27.07.2019
Verlag
Springer India
Erschienen in
Hepatology International / Ausgabe 5/2019
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-019-09967-y

Weitere Artikel der Ausgabe 5/2019

Hepatology International 5/2019 Zur Ausgabe

Original Article

Association between neutrophil–lymphocyte ratio, socioeconomic status, and ethnic minority with treatment outcome in hepatocellular carcinoma

Original Article

Sequential combination therapy with interferon, interleukin-2 and therapeutic vaccine in entecavir-suppressed chronic hepatitis B patients: the Endeavor study

Editorial

Prognostic four-gene signature for overall survival in patients with hepatocellular carcinoma

Review Article

Reversal of NASH fibrosis with pharmacotherapy

Original Article

An imbalance between stellate cells and γδT cells contributes to hepatocellular carcinoma aggressiveness and recurrence

Original Article

Asparaginase-induced hepatotoxicity: rapid development of cholestasis and hepatic steatosis

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 | Hypertonie | Nachrichten

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 | Parkinson-Krankheit | Nachrichten

Viel Bewegung in der Parkinsonforschung

25.04.2024 | Nierenkarzinom | Nachrichten

Adjuvante Immuntherapie verlängert Leben bei RCC
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise